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ABSTRACT: Castleman disease (CD) describes a heterogeneous group of rare and poorly understood lymphoproliferative disorders that 
can involve flu-like symptoms, multiple organ system dysfunction, and even death. Prior to 2012, the limited and disparate resources, 
including clinical data, tissue samples, and research funding, prevented the medical community from making positive strides towards 
understanding the pathogenesis of CD. The Castleman Disease Collaborative Network (CDCN) was created in 2012 to accelerate research 
and drug development for CD by facilitating global collaboration, strategically investing in high impact research, and engaging patients 
throughout the research process. The CDCN’s global collaborative network has been crucial for accelerating the understanding of CD. 
Together, the CDCN has already helped establish a uniform terminology system and a new model of pathogenesis. With the CDCN’s 
network in place and an ambitious international research agenda, further breakthroughs for CD are on the horizon. In this paper, we 
report three examples of how global collaboration has helped to advance CD research, which we believe can serve as models for other 
research networks and international investigators. 
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BACKGROUND
Castleman Disease (CD) is a rare and potentially fatal disease with approximately 6,500 
to 7,700 new cases diagnosed each year in the United 
States1. CD describes a heterogeneous group of three 
lymphoproliferative disorders that range from a single 
region of enlarged lymph nodes with few symptoms 
(unicentric CD) to multiple enlarged lymph nodes 
with flu-like symptoms, fluid accumulation, and even 
deadly multiple organ system failure (multicentric CD). 
Unicentric CD is often cured with surgical intervention2. 
Multicentric CD (MCD) is caused by excessive release of 
proinflammatory cytokines including interleukin-6 (IL-6)3. 
MCD is further subclassified into Human Herpes Virus-8 
(HHV-8) associated MCD (HHV-8-associated MCD) and 
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HHV-8 negative or idiopathic MCD (iMCD)1. In HHV-
8-associated MCD, the inflammatory cascade is caused 
by HHV-8 replication in B-cells, which release IL-6 and 
other pro-inflammatory cytokines4. Treatment of HHV-8-
associated MCD patients with rituximab, which depletes 
B-cells, is highly effective in these patients5. In iMCD, a 
similar inflammatory cascade occurs, but there is no HHV-8 
and the cause of the inflammatory cascade, key immune 
cells, and key immune pathways remain unknown6. With 
an unknown etiology and pathogenesis, iMCD is difficult 
to treat, leading to an array of attempted treatments with 
variable success. A major breakthrough occurred in 2014 
when siltuximab, a monoclonal antibody that neutralizes 
IL-6, became the first FDA-approved treatment for iMCD7. 
However, siltuximab only elicited a partial or complete 
response in 34 percent of patients in the clinical trial. 
Research is urgently needed to elucidate the pathogenesis 
of iMCD in order to identify treatments for the two-thirds 
of patients who do not respond to siltuximab7.
Like many rare diseases, there are several systemic 
factors that have slowed down progress for CD research 
and treatment. One major barrier for iMCD research was 
the lack of centralized clinical and research data. With no 
database to track treatments, physicians were left to make 
care decisions based on their own intuition, with little 
data to inform their choices8. Additionally, tissue samples 
were very difficult to locate for research as there was no 
centralized biorepository. The limited number of tissue 
samples for research has prevented investigators without 
access to samples from studying CD.8 The scarcity of tissue 
samples also contributed to the lack of federal funding for 
research. Since researchers did not have enough samples 
to generate sufficient preliminary data, they have not been 
in a position to apply for competitive federal funding. In 
fact, to date, iMCD researchers have never received NIH 
grants, which are a crucial funding source that other rare 
diseases have successfully leveraged8. Finally, researchers 
in different parts of the world were not using common 
terminology systems, so it was difficult to understand 
how research studies could build upon one another. It was 
clear that building a collaborative network was urgently 
needed to centralize clinical data and tissue samples, 
promote the sharing of samples to achieve larger sample 
sizes and generate preliminary data for federal funding, 
establish a unified terminology system, and drive forward 
an international research agenda. 
In 2012, Dr. David Fajgenbaum joined together 
a team of fellow physicians, researchers, and patients 
to create the Castleman Disease Collaborative Network 
(CDCN)8. The first phase of the CDCN was to create a 
collective global community that would work together 
in order to improve treatments and eventually cure CD8. 
Physicians and researchers from around the world were 
identified through PubMed searches and connected 
through an online discussion board and in-person meetings. 
An international Scientific Advisory Board (SAB) was 
established to prioritize research projects and set the overall 
direction of the organization9. The CDCN also supported 
and engaged patients and loved ones in the advancement 
of CD research9. See Figure 1 for a map demonstrating the 
distribution of physicians and researchers in the CDCN 
network from around the world today. See Figure 2 for a 
map demonstrating the distribution of patients in the CDCN 
network from around the word today.
Figure 1. Worldwide distribution of the 317 CD physicians and researchers connected through the CDCN
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Figure 2. Worldwide distribution of the 372 patients with CD registered with the CDCN
The second phase of the CDCN was focused on 
leveraging the community to prioritize research projects8. 
The CDCN reached out to their new collaborative 
community to gather information on what was currently 
known about the disease and what needed to be done 
in the future. The future projects were prioritized based 
on their feasibility and impact, with the idea that the 
entire global community agreed upon and would support 
this list. The third phase of the CDCN was to execute 
prioritized projects through proactive and reactive funding 
mechanisms8. Funding was sought from philanthropic and 
industry stakeholders and distributed to the top experts to 
carry out the studies that had been deemed high priority8. 
Together, the CDCN has established a unified terminology 
system along with a new model of iMCD pathogenesis. 
Today, the CDCN includes a global network of over 300 
physicians and researchers working together to advance 
the CDCN’s community-prioritized international research 
agenda by sharing clinical data and tissue samples as well 
as conducting research. The CDCN has organized the four 
largest CD research meetings, hosted two international 
Castleman Disease Pathology workshops, and coordinated 
two summits that brought together CD patients and loved 
ones from around the world10.
The success of the CDCN has been a result of its 
focus on global collaboration. Herein, we report three 
mini-case examples of how global collaboration has helped 
to advance CD research, which we believe can serve as 
examples for other research networks and international 
researchers.
Mini Case Report #1: The Pathogen Discovery Study 
In iMCD, an inflammatory cascade occurs, but, as 
discussed above, the cause and drivers of the inflammatory 
cascade are unknown2. There are currently three hypotheses 
that may explain the pathologic hypercytokinemia that 
drives iMCD: autoimmune mechanisms, paraneoplastic 
secretion of proinflammatory cytokines by malignant 
cells, and infection with an unknown virus11. iMCD’s 
overlapping clinical and laboratory features with HHV-8 
MCD suggest that an unknown virus may be responsible 
for iMCD. Additionally, pathogens such as Hepatitis B 
and gamma-herpesvirus members Epstein-Barr Virus and 
Human Herpesvirus 6 have been reported in case reports 
associated with iMCD11.
In order to investigate the hypothesis that a virus 
may be responsible for iMCD, the CDCN contracted with 
the Center for Infection and Immunity (CII) at Columbia 
University to perform a pathogen discovery study. Nucleic 
acids will be isolated from lymph nodes, the RNA pool 
will be reverse transcribed and PCR amplified to generate 
a sequencing library, and the sequencing libraries will then 
go through a pipeline to identify potential candidates11. 
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Unfortunately, CII would need at least 25 lymph nodes 
samples from a variety of disease states to perform this 
study, and the lymph node samples must be flash-frozen 
since RNA is sensitive to degradation during fixation11. 
Lymph nodes are almost never frozen when removed 
clinically, and the CDCN was pessimistic about being able 
to identify enough samples for the study.
In response to this problem, the CDCN recognized 
the need for global collaboration in order to gather enough 
samples for the study. It turned to its international network 
of over 300 physicians and researchers and identified 34 
viable samples from seven different institutions. Once 
the samples were located and the collaborators were 
on board with the study, the CDCN assisted with the 
logistics of Institutional Review Board (IRB) approvals, 
patient consent from the tissue donors, Material Transfer 
Agreements with both Columbia University and its 
collaborators, and coordination of shipping. Nearly all 
of the samples have arrived at Columbia University, and 
the CDCN expects to have data back on this key study by 
mid-2016. This potentially groundbreaking study could not 
have been performed by a single institution, as it required 
global collaboration.
Mini Case Report #2: The Global Patient Registry 
One of the greatest barriers to successfully treating 
iMCD has been the lack of a database to track treatments 
and patient care, leaving physicians to make care decisions 
with limited data. The CDCN aims to solve this problem 
by creating a global registry (ACCELERATE) that will 
collect real-world demographic, clinical, laboratory, 
patient-reported outcomes, and treatment data on patients 
with CD12. Such a registry could help to guide physicians 
in making more informed, evidence-based decisions when 
treating patients with CD. The CDCN has engaged and 
partnered with a top pharmaceutical company to build this 
registry at the University of Pennsylvania12.
The registry will focus on enrolling patients from 
Europe and North America, but patients from anywhere 
around the world will be able to enroll as well. In Europe, 
patients will be enrolled by participating physicians from 
10 study sites with medical record data entry by site staff 
and optional patient-reported data entry. In North America 
and other countries outside of Europe, patients will self-
enroll, and the ACCELERATE Registry Team will perform 
medical record data entry.
The creation of this registry will benefit the 
international Castleman disease community in three 
important ways: it will track the natural history of the 
disease, track real-world treatment use and safety profiles, 
and build an infrastructure for future translational research 
by collecting clinical data and tissue samples13. The 
results of the registry will improve understanding of CD 
at the international level. A successful registry requires 
a community of physicians, researchers, and patients to 
work together to prioritize research questions, actively 
participate, and contribute data for the registry. The 
CDCN’s international community, scientific advisory board 
(SAB) of experts, and strong patient community will enable 
the ACCELERATE team to recruit the number and type of 
patients needed for the registry8.
Mini Case Report #3: The Importance of Studying 
Regional Differences 
The pursuit of global collaboration is crucial 
in studying a rare disease, since similar pathology can 
present itself asynchronously in different parts of the 
world. Accordingly, Castleman disease clinical symptoms 
can vary across geographic regions. In a Japanese clinical 
trial, baseline measurements demonstrated that 17 of 26 
had lymphocytic interstitial pneumonitis and 12 of 26 
had violaceous, lymphocytic skin lesions1. These findings 
are notable, because patients with iMCD in other regions 
almost never demonstrate these features. Recognizing these 
geographic differences is imperative in conducting sound 
scientific research.
Varied presentations across geographies are not 
unique to iMCD. Epstein-Barr Virus (EBV) is found widely 
across the world but presents itself in different ways in 
different regions of the world. The two types of EBV (1 
and 2) differ in their geographic distribution6; Type 1 is 
most common as a whole across the world, but Type 2 is 
more prevalent in Africa, Papua New Guinea, and Alaska14. 
In Central Africa and Papua New Guinea, EBV-infected 
patients show the clinical condition of Burkitt’s lymphoma, 
while their Asian counterparts show the clinical condition 
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of nasopharyngeal carcinoma14. When approaching CD, 
it is important to keep in mind that global collaboration 
is crucial in order to recognize potential etiological and 
pathological differences in CD across the world.
It is not known why East Asian patients (either 
born in East Asia or of East Asian ancestry born in other 
regions) express different clinical symptoms than other 
patient populations. One hypothesis accounting for the 
variation is genotype differences. An alternate hypothesis 
is the possibility of a different pathogen or subtype of a 
pathogen responsible for CD in different regions. Further 
research is needed to discover the cause for iMCD and 
address these clinical differences.
A collaborative global network is also important in 
order for physicians and researchers to quickly disseminate 
discoveries in other countries. In Japan, a subset of iMCD 
patients found to demonstrate similar symptoms was 
identified and described as “TAFRO” syndrome15. These 
patients demonstrated Thrombocytopenia, Anasarca, Fever, 
Reticulin fibrosis, and Organomegaly. Initially, researchers 
in Japan considered this subtype of iMCD to be unique to 
Japan.  However, members of the CDCN posted on the 
group’s online forum about cases in North America and 
throughout Europe with TAFRO syndrome, suggesting that 
these features can be seen outside of Japan. Compared to 
iMCD patients without TAFRO syndrome, iMCD patients 
with TAFRO syndrome have a more aggressive clinical 
course, and the CDCN is focused on studying this subtype 
in patients around the world.
Challenges
Global collaboration has been essential for 
improving the understanding and treatment of CD. 
Nevertheless, there are several important challenges that 
come with global collaborations, such as language barriers 
and the use of different terminology systems to describe 
subtypes of the disease in different regions, which may 
cause misinterpretation. Furthermore, extended travel times 
for shipping samples between countries and inter-country 
shipping barriers can impede collaboration. Lastly, a global 
community is very difficult to connect for face-to-face 
meetings. 
CONCLUSION
CD is a complicated and potentially fatal disease 
that requires global collaboration among physicians, 
researchers, and patients in order to improve the knowledge 
and treatment of the disease. Prior to the formation of the 
CDCN, there was little, if any, global collaboration in CD 
research, and the outlook for the disease was poor. The 
CDCN’s emphasis on global collaboration has facilitated 
the advancement in understanding of CD in a variety of 
realms. A Pathogen Discovery Study was launched that 
could potentially explain the etiology of iMCD which 
could not have been possible at any one institution. The 
CDCN’s global network provides the infrastructure needed 
to build a global registry and to enroll the requisite patients. 
Finally, the CDCN’s global reach has helped to identify 
epidemiological and phenotypic differences and similarities 
in CD across regions that could never have been reviewed 
without the CDCN’s network. Global collaboration has 
its challenges, but it also provides a great deal of hope for 
advancing understanding of CD and moving closer to a 
cure. We hope that the CDCN’s model and these mini-case 
studies can be useful to other rare disease organizations to 
facilitate global collaboration. 
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